Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2005-11-1
pubmed:abstractText
Gout and calcium pyrophosphate deposition disease are two common causes of inflammatory joint disease. Despite differences underlying their pathogenesis, their clinical presentation and treatment share some common features. Optimal treatment for both requires prompt resolution of acute synovitis, reduction of chronic joint damage and management of associated conditions. Available therapeutic interventions and future strategies are reviewed in this article.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones, http://linkedlifedata.com/resource/pubmed/chemical/Adrenocorticotropic Hormone, http://linkedlifedata.com/resource/pubmed/chemical/Allopurinol, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents..., http://linkedlifedata.com/resource/pubmed/chemical/Colchicine, http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Gout Suppressants, http://linkedlifedata.com/resource/pubmed/chemical/Probenecid, http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles, http://linkedlifedata.com/resource/pubmed/chemical/Uric Acid, http://linkedlifedata.com/resource/pubmed/chemical/Uricosuric Agents, http://linkedlifedata.com/resource/pubmed/chemical/Xanthine Oxidase, http://linkedlifedata.com/resource/pubmed/chemical/febuxostat
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1744-7666
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2443-53
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16259576-Adrenal Cortex Hormones, pubmed-meshheading:16259576-Adrenocorticotropic Hormone, pubmed-meshheading:16259576-Allopurinol, pubmed-meshheading:16259576-Animals, pubmed-meshheading:16259576-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:16259576-Arthritis, Gouty, pubmed-meshheading:16259576-Chondrocalcinosis, pubmed-meshheading:16259576-Colchicine, pubmed-meshheading:16259576-Drug Combinations, pubmed-meshheading:16259576-Enzyme Inhibitors, pubmed-meshheading:16259576-Gout, pubmed-meshheading:16259576-Gout Suppressants, pubmed-meshheading:16259576-Humans, pubmed-meshheading:16259576-Multicenter Studies as Topic, pubmed-meshheading:16259576-Probenecid, pubmed-meshheading:16259576-Randomized Controlled Trials as Topic, pubmed-meshheading:16259576-Thiazoles, pubmed-meshheading:16259576-Uric Acid, pubmed-meshheading:16259576-Uricosuric Agents, pubmed-meshheading:16259576-Xanthine Oxidase
pubmed:year
2005
pubmed:articleTitle
An update on the treatment options for gout and calcium pyrophosphate deposition.
pubmed:affiliation
Division of Rheumatology, University of Toronto, Sunnybrook and Women's College Health Science Centre, M1-401, Toronto, ON, M4N 3M5, Canada.
pubmed:publicationType
Journal Article, Review